| [1] |
Schön MP, Boehncke WH. Psoriasis[J]. N Engl J Med, 2005, 352(18): 1899⁃1912. DOI: 10.1056/NEJMra041320.
|
| [2] |
Luber AJ, Tsui CL, Heinecke GM, et al. Long⁃term durability and dose escalation patterns in infliximab therapy for psoriasis[J]. J Am Acad Dermatol, 2014, 70(3): 525⁃532. DOI: 10.1016/j.jaad.2013.10.059.
|
| [3] |
Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infli⁃ximab clearance and shorten half⁃life in inflammatory bowel disease: a population pharmacokinetic study[J]. Inflamm Bowel Dis, 2014, 20(12): 2247⁃2259. DOI: 10.1097/MIB.0000000000000212.
|
| [4] |
Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial[J]. J Am Acad Dermatol, 2004, 51(4): 534⁃542. DOI: 10.1016/j.jaad.2004.02.021.
|
| [5] |
Wetter DA, Davis MD. Lupus⁃like syndrome attributable to anti⁃tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic[J]. Mayo Clin Proc, 2009, 84(11): 979⁃984. DOI: 10.4065/84.11.979.
|
| [6] |
朱晨雨, 孙秋宁, 舒畅, 等. 英夫利西单抗治疗重度银屑病17例临床观察[J]. 中华皮肤科杂志, 2016, 49(4): 294⁃295. DOI: 10.3760/cma.j.issn.0412⁃4030.2016.04.021.
|
|
Zhu Chenyu, Sun Qiuning, Shu Chang, et al. Infliximab for the treatment of severe psoriasis in 17 cases: a clinical observational study[J]. Chin J Dermatol, 2016, 49(4): 294⁃295. DOI: 10.3760/cma.j.issn.0412⁃4030.2016.04.021.
|